Quoin Pharmaceuticals announced the appointment of Sally Lawlor as its new Chief Financial Officer.
Ms. Lawlor brings over 20 years of finance executive experience to Quoin Pharmaceuticals.
She will play a crucial role in guiding the company through commercialization and financial planning.
New CFO Appointment
Sally Lawlor, BCL, FCA, appointed as Chief Financial Officer with extensive finance leadership experience.
Clinical Trials Progress
Quoin is conducting pivotal clinical studies for QRX003 in Netherton Syndrome with full enrollment expected by early to mid-Q1 2026.
Pipeline Development
Quoin has development programs for Peeling Skin Syndrome and a novel rapamycin platform targeting rare dermatologic diseases.
- The appointment of Sally Lawlor signifies Quoin's focus on advancing towards commercialization.
- With ongoing clinical trials and pipeline development, Quoin aims to address unmet medical needs in rare diseases.
The addition of Sally Lawlor as Chief Financial Officer will strengthen Quoin Pharmaceuticals' financial leadership during a crucial growth phase. The company's strategic focus on rare disease treatments shows promise for the future of healthcare innovation.